T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EA
701
DELISTED
Electronic Arts
EA
| $72.7M | 0.01% |
355,840
-1,048,184
| -75% | -$212M |
|
702
Immunome
IMNM
$3B
| $72.6M | 0.01% |
3,380,240
-362,530
| -10% | -$6.36M |
|
703
Exelon
EXC
$47B
| $72.5M | 0.01% |
1,663,722
-1,496,014
| -47% | -$68.3M |
|
704
Novanta
NOVT
$6.33B
| $72.4M | 0.01% |
608,426
-364,003
| -37% | -$41.5M |
|
705
Paychex
PAYX
$44.6B
| $72.3M | 0.01% |
644,089
+2,833
| +0.4% | +$332K |
|
706
Leonardo DRS
DRS
$11.9B
| $71.6M | 0.01% |
2,100,982
-470,807
| -18% | -$17.4M |
|
707
Conagra Brands
CAG
$7.39B
| $71.4M | 0.01% |
4,123,906
-522,390
| -11% | -$9.28M |
|
708
Adaptive Biotechnologies
ADPT
$3.89B
| $71.3M | 0.01% |
4,387,361
+3,299,635
| +303% | +$53.9M |
|
709
Construction Partners
ROAD
$6.73B
| $70.7M | 0.01% |
651,699
-181,559
| -22% | -$20.4M |
|
710
Pebblebrook Hotel Trust
PEB
$2.05B
| $70M | 0.01% |
6,180,800
+711,042
| +13% | +$7.83M |
|
711
Affiliated Managers Group
AMG
$9.7B
| $69.8M | 0.01% |
242,292
-1,961
| -0.8% | -$507K |
|
712
Abercrombie & Fitch
ANF
$4.84B
| $69.8M | 0.01% |
554,816
-1,510
| -0.3% | -$132K |
|
713
Transmedics
TMDX
$3.11B
| $69.3M | 0.01% |
569,970
+171,810
| +43% | +$21.6M |
|
714
T. Rowe Price Dividend Growth ETF
TDVG
$1.45B
| $68.6M | 0.01% |
1,525,001
| – | – |
|
715
Intapp
INTA
$3.16B
| $67.7M | 0.01% |
1,478,394
+582,419
| +65% | +$24.2M |
|
|
FIG
716
Figma
FIG
$14B
| $67.3M | 0.01% |
1,802,046
+1,678,135
| +1,354% | +$75.8M |
|
717
Primoris Services
PRIM
$4.35B
| $66.4M | 0.01% |
534,543
+2,685
| +0.5% | +$351K |
|
718
Applied Industrial Technologies
AIT
$13.2B
| $66.2M | 0.01% |
257,935
-158,355
| -38% | -$40.5M |
|
719
Interactive Brokers
IBKR
$41.4B
| $66.2M | 0.01% |
1,029,793
+77,027
| +8% | +$5.16M |
|
720
Apple Hospitality REIT
APLE
$3.75B
| $66.2M | 0.01% |
5,585,826
-62,452
| -1% | -$733K |
|
721
Delta Air Lines
DAL
$60B
| $65.9M | 0.01% |
950,144
+758
| +0.1% | +$47.4K |
|
722
TransUnion
TRU
$15.5B
| $65.9M | 0.01% |
768,111
-590,578
| -43% | -$48.5M |
|
723
Ferguson
FERG
$48B
| $65.7M | 0.01% |
295,054
+56,254
| +24% | +$13.4M |
|
724
Option Care Health
OPCH
$3.61B
| $65.7M | 0.01% |
2,061,494
-34,845
| -2% | -$1.02M |
|
725
Medpace
MEDP
$16.2B
| $65.5M | 0.01% |
116,581
+14,253
| +14% | +$8.09M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.